Skip to main content
Top
Published in: Thrombosis Journal 1/2021

Open Access 01-12-2021 | Dabigatran | Research

Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms

Authors: Simon T. Schäfer, Anne-Christine Otto, Alice-Christin Acevedo, Klaus Görlinger, Steffen Massberg, Tobias Kammerer, Philipp Groene

Published in: Thrombosis Journal | Issue 1/2021

Login to get access

Abstract

Background

DOAC detection is challenging in emergency situations. Here, we demonstrated recently, that modified thromboelastometric tests can reliably detect and differentiate dabigatran and rivaroxaban. However, whether all DOACs can be detected and differentiated to other coagulopathies is unclear. Therefore, we now tested the hypothesis that a decision tree-based thromboelastometry algorithm enables detection and differentiation of all direct Xa-inhibitors (DXaIs), the direct thrombin inhibitor (DTI) dabigatran, as well as vitamin K antagonists (VKA) and dilutional coagulopathy (DIL) with high accuracy.

Methods

Following ethics committee approval (No 17–525-4), and registration by the German clinical trials database we conducted a prospective observational trial including 50 anticoagulated patients (n = 10 of either DOAC/VKA) and 20 healthy volunteers. Blood was drawn independent of last intake of coagulation inhibitor. Healthy volunteers served as controls and their blood was diluted to simulate a 50% dilution in vitro. Standard (extrinsic coagulation assay, fibrinogen assay, etc.) and modified thromboelastometric tests (ecarin assay and extrinsic coagulation assay with low tissue factor) were performed. Statistical analyzes included a decision tree analyzes, with depiction of accuracy, sensitivity and specificity, as well as receiver-operating-characteristics (ROC) curve analysis including optimal cut-off values (Youden-Index).

Results

First, standard thromboelastometric tests allow a good differentiation between DOACs and VKA, DIL and controls, however they fail to differentiate DXaIs, DTIs and VKAs reliably resulting in an overall accuracy of 78%. Second, adding modified thromboelastometric tests, 9/10 DTI and 28/30 DXaI patients were detected, resulting in an overall accuracy of 94%. Complex decision trees even increased overall accuracy to 98%. ROC curve analyses confirm the decision-tree-based results showing high sensitivity and specificity for detection and differentiation of DTI, DXaIs, VKA, DIL, and controls.

Conclusions

Decision tree-based machine-learning algorithms using standard and modified thromboelastometric tests allow reliable detection of DTI and DXaIs, and differentiation to VKA, DIL and controls.

Trial registration

Clinical trial number: German clinical trials database ID: DRKS00015704.
Appendix
Available only for authorised users
Literature
6.
go back to reference Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, et al. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018;16:462–70.PubMedPubMedCentral Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, et al. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018;16:462–70.PubMedPubMedCentral
21.
go back to reference Groene P, Wiederkehr T, Kammerer T, Acevedo A, Brummer V, Feil K, et al. Neuartiger POC-Test detektiert die Wirkung direkter oraler Antikoagulantien (DOAK) und diskriminiert zwischen Dabigatran und Rivaroxaban in vitro und in vivo. Anästh Intensivmed. 2019;60:344–80. Groene P, Wiederkehr T, Kammerer T, Acevedo A, Brummer V, Feil K, et al. Neuartiger POC-Test detektiert die Wirkung direkter oraler Antikoagulantien (DOAK) und diskriminiert zwischen Dabigatran und Rivaroxaban in vitro und in vivo. Anästh Intensivmed. 2019;60:344–80.
30.
go back to reference Breimann L, Friedmann J, Stone C, Olshen R. Classification and regression trees, Taylor & Francis ltd. Auflage: UK ed; 1984. Breimann L, Friedmann J, Stone C, Olshen R. Classification and regression trees, Taylor & Francis ltd. Auflage: UK ed; 1984.
35.
go back to reference Margetić S, Ćelap I, Delić Brkljačić D, Pavlović N, Šupraha Goreta S, Kobasić I, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med. 2020;30:010702.CrossRef Margetić S, Ćelap I, Delić Brkljačić D, Pavlović N, Šupraha Goreta S, Kobasić I, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med. 2020;30:010702.CrossRef
36.
go back to reference Ebner M, Birschmann I, Peter A, Härtig F, Spencer C, Kuhn J, et al. Limitations of specific coagulation tests for direct Oral anticoagulants: a critical analysis. J Am Heart Assoc. 2018;7:e009807.CrossRef Ebner M, Birschmann I, Peter A, Härtig F, Spencer C, Kuhn J, et al. Limitations of specific coagulation tests for direct Oral anticoagulants: a critical analysis. J Am Heart Assoc. 2018;7:e009807.CrossRef
49.
go back to reference J. Boyd, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guidelines, CLSI document C28-A3, Vol. 28, No. 3, 2010. J. Boyd, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guidelines, CLSI document C28-A3, Vol. 28, No. 3, 2010.
Metadata
Title
Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms
Authors
Simon T. Schäfer
Anne-Christine Otto
Alice-Christin Acevedo
Klaus Görlinger
Steffen Massberg
Tobias Kammerer
Philipp Groene
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-021-00313-7

Other articles of this Issue 1/2021

Thrombosis Journal 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.